# Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 21, 2025

## Cell4Cure (C4C) Consortium

RRID:SCR_013679
Type: Tool

### Proper Citation

Cell4Cure (C4C) Consortium (RRID:SCR_013679)

### Resource Information

**URL:** http://www.cellforcure.com/en/pages/c4c-project

**Proper Citation:** Cell4Cure (C4C) Consortium (RRID:SCR_013679)

**Description:** The Cell4Cure consortium aims to advance the cGMP production of therapeutic cell therapies. The consortium is led by Cellectis, a biotech focused in the development of adoptive immunotherapies and CELLforCURE, the largest commercial industrial facility for the production of therapeutic cell therapies in Europe. The consortium also includes seven public-sector organizations and university medical centers, who collaborate with the private sector companies.

**Abbreviations:** C4C

**Resource Type:** data or information resource, organization portal, portal, consortium

**Keywords:** therapeutic, cell therapies, immunotherapy, drug development, product development,

**Funding:** Consortium members ;
French government

**Resource Name:** Cell4Cure (C4C) Consortium

**Resource ID:** SCR_013679

**Record Creation Time:** 20220129T080317+0000

**Record Last Update:** 20250521T061513+0000

### Ratings and Alerts

No rating or validation information has been found for Cell4Cure (C4C) Consortium.

No alerts have been found for Cell4Cure (C4C) Consortium.

## Data and Source Information

**Source:** SciCrunch Registry

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.

Jakob MO, et al. (2023) ILC3s restrict the dissemination of intestinal bacteria to safeguard liver regeneration after surgery. Cell reports, 42(3), 112269.